Use of dapagliflozin in patients with advanced diabetic kidney disease
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are effective for overweight diabetic patients through the induction of glucosuria. However, SGLT2 inhibitors are not recommended for patients with advanced chronic kidney disease (CKD) because they may aggravate renal function and thus become less e...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Society of Nephrology
2018-09-01
|
| Series: | Kidney Research and Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.23876/j.krcp.2018.37.3.292 |